JP2012528792A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012528792A5 JP2012528792A5 JP2012513319A JP2012513319A JP2012528792A5 JP 2012528792 A5 JP2012528792 A5 JP 2012528792A5 JP 2012513319 A JP2012513319 A JP 2012513319A JP 2012513319 A JP2012513319 A JP 2012513319A JP 2012528792 A5 JP2012528792 A5 JP 2012528792A5
- Authority
- JP
- Japan
- Prior art keywords
- particles
- active agent
- suspension
- pharmaceutical composition
- species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims 95
- 239000013543 active substance Substances 0.000 claims 42
- 239000000725 suspension Substances 0.000 claims 33
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 229940071648 metered dose inhaler Drugs 0.000 claims 20
- 241000894007 species Species 0.000 claims 20
- 239000012190 activator Substances 0.000 claims 17
- 239000000443 aerosol Substances 0.000 claims 16
- 229960002848 formoterol Drugs 0.000 claims 12
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 12
- 230000036470 plasma concentration Effects 0.000 claims 12
- 150000002148 esters Chemical class 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 11
- 239000012453 solvate Substances 0.000 claims 11
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 10
- 229940015042 glycopyrrolate Drugs 0.000 claims 10
- 238000000034 method Methods 0.000 claims 10
- 239000003380 propellant Substances 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 239000013078 crystal Substances 0.000 claims 8
- 239000010419 fine particle Substances 0.000 claims 6
- 238000009472 formulation Methods 0.000 claims 6
- 230000008695 pulmonary vasoconstriction Effects 0.000 claims 6
- 239000003246 corticosteroid Substances 0.000 claims 5
- 230000003287 optical effect Effects 0.000 claims 5
- 206010061218 Inflammation Diseases 0.000 claims 4
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 230000004054 inflammatory process Effects 0.000 claims 4
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims 3
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 3
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims 3
- 230000010085 airway hyperresponsiveness Effects 0.000 claims 3
- 201000010105 allergic rhinitis Diseases 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 229940092705 beclomethasone Drugs 0.000 claims 3
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 3
- 229960004436 budesonide Drugs 0.000 claims 3
- 229960003728 ciclesonide Drugs 0.000 claims 3
- 229960001334 corticosteroids Drugs 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000005713 exacerbation Effects 0.000 claims 3
- 229960000676 flunisolide Drugs 0.000 claims 3
- 229960002714 fluticasone Drugs 0.000 claims 3
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims 3
- 238000002483 medication Methods 0.000 claims 3
- 229960004584 methylprednisolone Drugs 0.000 claims 3
- 229960001664 mometasone Drugs 0.000 claims 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 3
- 229960004618 prednisone Drugs 0.000 claims 3
- 208000002815 pulmonary hypertension Diseases 0.000 claims 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims 3
- 201000009890 sinusitis Diseases 0.000 claims 3
- 229960005294 triamcinolone Drugs 0.000 claims 3
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 claims 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- 206010061876 Obstruction Diseases 0.000 claims 2
- 206010035664 Pneumonia Diseases 0.000 claims 2
- 206010038687 Respiratory distress Diseases 0.000 claims 2
- 230000001133 acceleration Effects 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims 2
- 239000001110 calcium chloride Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 238000001694 spray drying Methods 0.000 claims 2
- 230000002123 temporal effect Effects 0.000 claims 2
- BLUGYPPOFIHFJS-UUFHNPECSA-N (2s)-n-[(2s)-1-[[(3r,4s,5s)-3-methoxy-1-[(2s)-2-[(1r,2r)-1-methoxy-2-methyl-3-oxo-3-[[(1s)-2-phenyl-1-(1,3-thiazol-2-yl)ethyl]amino]propyl]pyrrolidin-1-yl]-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-3-methyl-2-(methylamino)butanamid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C=1SC=CN=1)CC1=CC=CC=C1 BLUGYPPOFIHFJS-UUFHNPECSA-N 0.000 claims 1
- BKLAJZNVMHLXAP-VKGMXUHCSA-N 3-[(1r,5s)-8,8-dimethyl-8-azoniabicyclo[3.2.1]octan-3-yl]-2,2-diphenylpropanenitrile Chemical compound C([C@H]1CC[C@@H](C2)[N+]1(C)C)C2CC(C#N)(C=1C=CC=CC=1)C1=CC=CC=C1 BKLAJZNVMHLXAP-VKGMXUHCSA-N 0.000 claims 1
- PZSMUPGANZGPBF-UHFFFAOYSA-N 4-[5-(dithiolan-3-yl)pentanoylamino]butanoic acid Chemical compound OC(=O)CCCNC(=O)CCCCC1CCSS1 PZSMUPGANZGPBF-UHFFFAOYSA-N 0.000 claims 1
- IHOXNOQMRZISPV-YJYMSZOUSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-methoxyphenyl)propan-2-yl]azaniumyl]ethyl]-2-oxo-1h-quinolin-8-olate Chemical compound C1=CC(OC)=CC=C1C[C@@H](C)NC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 IHOXNOQMRZISPV-YJYMSZOUSA-N 0.000 claims 1
- 208000007934 ACTH-independent macronodular adrenal hyperplasia Diseases 0.000 claims 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 claims 1
- 241000282838 Lama Species 0.000 claims 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 claims 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 claims 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 claims 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960003060 bambuterol Drugs 0.000 claims 1
- ANZXOIAKUNOVQU-UHFFFAOYSA-N bambuterol Chemical compound CN(C)C(=O)OC1=CC(OC(=O)N(C)C)=CC(C(O)CNC(C)(C)C)=C1 ANZXOIAKUNOVQU-UHFFFAOYSA-N 0.000 claims 1
- 229950010713 carmoterol Drugs 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 229960001117 clenbuterol Drugs 0.000 claims 1
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical compound CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims 1
- -1 dextyronium Chemical compound 0.000 claims 1
- 229960004078 indacaterol Drugs 0.000 claims 1
- QZZUEBNBZAPZLX-QFIPXVFZSA-N indacaterol Chemical compound N1C(=O)C=CC2=C1C(O)=CC=C2[C@@H](O)CNC1CC(C=C(C(=C2)CC)CC)=C2C1 QZZUEBNBZAPZLX-QFIPXVFZSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229940125389 long-acting beta agonist Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229950001768 milveterol Drugs 0.000 claims 1
- BMKINZUHKYLSKI-DQEYMECFSA-N n-[2-hydroxy-5-[(1r)-1-hydroxy-2-[2-[4-[[(2r)-2-hydroxy-2-phenylethyl]amino]phenyl]ethylamino]ethyl]phenyl]formamide Chemical compound C1([C@@H](O)CNC2=CC=C(C=C2)CCNC[C@H](O)C=2C=C(NC=O)C(O)=CC=2)=CC=CC=C1 BMKINZUHKYLSKI-DQEYMECFSA-N 0.000 claims 1
- 239000006199 nebulizer Substances 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- CQRYARSYNCAZFO-UHFFFAOYSA-N salicyl alcohol Chemical compound OCC1=CC=CC=C1O CQRYARSYNCAZFO-UHFFFAOYSA-N 0.000 claims 1
- 229960004017 salmeterol Drugs 0.000 claims 1
- 239000000375 suspending agent Substances 0.000 claims 1
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims 1
- 229940110309 tiotropium Drugs 0.000 claims 1
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N trospium Chemical compound [N+]12([C@@H]3CC[C@H]2C[C@H](C3)OC(=O)C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CCCC1 OYYDSUSKLWTMMQ-JKHIJQBDSA-N 0.000 claims 1
- 229960001491 trospium Drugs 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18256509P | 2009-05-29 | 2009-05-29 | |
| US61/182,565 | 2009-05-29 | ||
| US25817209P | 2009-11-04 | 2009-11-04 | |
| US61/258,172 | 2009-11-04 | ||
| US30936510P | 2010-03-01 | 2010-03-01 | |
| US61/309,365 | 2010-03-01 | ||
| US34553610P | 2010-05-17 | 2010-05-17 | |
| US61/345,536 | 2010-05-17 | ||
| PCT/US2010/036676 WO2010138884A2 (en) | 2009-05-29 | 2010-05-28 | Compositions, methods & systems for respiratory delivery of two or more active agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015084240A Division JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012528792A JP2012528792A (ja) | 2012-11-15 |
| JP2012528792A5 true JP2012528792A5 (enExample) | 2013-07-18 |
| JP5873013B2 JP5873013B2 (ja) | 2016-03-01 |
Family
ID=42269864
Family Applications (10)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513314A Active JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2012513319A Active JP5873013B2 (ja) | 2009-05-29 | 2010-05-28 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2012513311A Active JP5873012B2 (ja) | 2009-05-29 | 2010-05-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015199079A Withdrawn JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513314A Active JP5823383B2 (ja) | 2009-05-29 | 2010-05-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012513311A Active JP5873012B2 (ja) | 2009-05-29 | 2010-05-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015084226A Active JP6169639B2 (ja) | 2009-05-29 | 2015-04-16 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2015084240A Active JP6189356B2 (ja) | 2009-05-29 | 2015-04-16 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2015199079A Withdrawn JP2016041713A (ja) | 2009-05-29 | 2015-10-07 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2017125969A Active JP6492124B2 (ja) | 2009-05-29 | 2017-06-28 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
| JP2017149555A Active JP6348645B2 (ja) | 2009-05-29 | 2017-08-02 | ２つ以上の活性剤を呼吸器送達するための組成物、方法および系 |
| JP2017188628A Pending JP2018048150A (ja) | 2009-05-29 | 2017-09-28 | 長時間作用性のムスカリン拮抗剤および長時間作用性のβ２アドレナリン受容体作動剤を肺送達するための組成物ならびに関連の方法および系 |
| JP2019038501A Active JP6876734B2 (ja) | 2009-05-29 | 2019-03-04 | 活性剤を呼吸器送達するための組成物、ならびに関連する方法および系 |
Country Status (31)
| Country | Link |
|---|---|
| US (12) | US8808713B2 (enExample) |
| EP (6) | EP2435024B1 (enExample) |
| JP (10) | JP5823383B2 (enExample) |
| KR (7) | KR20190049943A (enExample) |
| CN (6) | CN107412212B (enExample) |
| AR (3) | AR076621A1 (enExample) |
| AU (3) | AU2010253770B9 (enExample) |
| BR (3) | BRPI1011220B1 (enExample) |
| CA (3) | CA2763939A1 (enExample) |
| CY (8) | CY1118040T1 (enExample) |
| DK (6) | DK2435023T3 (enExample) |
| ES (6) | ES2593429T3 (enExample) |
| FR (1) | FR19C1040I2 (enExample) |
| HR (6) | HRP20161098T1 (enExample) |
| HU (8) | HUE047834T2 (enExample) |
| IL (3) | IL216466B (enExample) |
| LT (8) | LT3106149T (enExample) |
| LU (2) | LUC00124I2 (enExample) |
| ME (1) | ME03631B (enExample) |
| MX (5) | MX393243B (enExample) |
| NL (1) | NL300995I2 (enExample) |
| NO (2) | NO2019026I1 (enExample) |
| PH (1) | PH12017500778A1 (enExample) |
| PL (6) | PL3111927T3 (enExample) |
| PT (6) | PT2435024T (enExample) |
| RU (5) | RU2751771C2 (enExample) |
| SI (6) | SI3106149T1 (enExample) |
| SM (6) | SMT202000108T1 (enExample) |
| TW (9) | TWI695723B (enExample) |
| WO (3) | WO2010138862A2 (enExample) |
| ZA (4) | ZA201108275B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| HUE025151T2 (en) | 2004-08-23 | 2016-01-28 | Mannkind Corp | Diceto-piperazine salts for drug delivery |
| US10002325B2 (en) | 2005-03-30 | 2018-06-19 | Primal Fusion Inc. | Knowledge representation systems and methods incorporating inference rules |
| KR101486397B1 (ko) | 2005-09-14 | 2015-01-28 | 맨카인드 코포레이션 | 활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법 |
| KR20080096809A (ko) | 2006-02-22 | 2008-11-03 | 맨카인드 코포레이션 | 디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법 |
| US10675417B2 (en) * | 2006-03-07 | 2020-06-09 | Leibovici, Llc | Method and apparatus for applying an anesthetic and bactericide |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2929343T3 (es) | 2008-06-13 | 2022-11-28 | Mannkind Corp | Inhalador de polvo seco accionado por aspiración para la administración de fármacos |
| MX2010014240A (es) | 2008-06-20 | 2011-03-25 | Mankind Corp | Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion. |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| SI3106149T1 (sl) * | 2009-05-29 | 2020-07-31 | Pearl Therapeutics, Inc. | Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi |
| BR112012033060A2 (pt) * | 2010-06-21 | 2018-02-27 | Mannkind Corp | métodos de sistema de liberação de fármaco em pó seco |
| US10474647B2 (en) | 2010-06-22 | 2019-11-12 | Primal Fusion Inc. | Methods and devices for customizing knowledge representation systems |
| AU2012236150B2 (en) | 2011-04-01 | 2016-03-31 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| MX2013013440A (es) * | 2011-05-17 | 2014-06-05 | Pearl Therapeutics Inc | Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos. |
| CN105106200A (zh) * | 2011-05-17 | 2015-12-02 | 珍珠治疗公司 | 用于呼吸递送两种或多种活性剂的组合物、方法和系统 |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| GB201113662D0 (en) * | 2011-08-08 | 2011-09-21 | Prosonix Ltd | Pharmaceutical compositions |
| BR112014009686A2 (pt) | 2011-10-24 | 2018-08-07 | Mannkind Corp | composição analgésica inalável, pó seco e método para tratar dor |
| BR112014025518B1 (pt) * | 2012-04-13 | 2022-05-24 | Glaxosmithkline Intellectual Property Development Limited | Partículas agregadas de umeclidinium, vilanterol e fluticasona, composição em pó, inalador, processo para a preparação de partículas agregadas, e, uso de estearato de magnésio em partículas agregadas |
| AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
| CN102872027B (zh) * | 2012-09-18 | 2014-03-12 | 刘晓忠 | 一种治疗肺部疾病的药物颗粒的制备和吸入式复方气雾剂的制备 |
| DK2948148T3 (da) * | 2013-01-28 | 2020-10-26 | Incozen Therapeutics Pvt Ltd | Metoder til behandling af autoimmune, åndedræts- og betændelsesforstyrrelser ved inhalation af roflumilast n-oxid |
| AU2014210942A1 (en) * | 2013-01-31 | 2015-08-20 | Prosonix Limited | Pharmaceutical compositions comprising multi-component crystalline particles suitable for use in inhalation therapy |
| GB201301721D0 (en) * | 2013-01-31 | 2013-03-20 | Prosonix Ltd | Pharmaceutical Preparations |
| HRP20201103T1 (hr) * | 2013-03-04 | 2021-02-05 | Besins Healthcare Luxembourg Sarl | Suhi farmaceutski pripravci koji sadrže nanočestice aktivnog sredstva vezane za čestice nosača |
| CA2898700C (en) * | 2013-03-14 | 2022-07-19 | Novartis Ag | Deamorphization of spray-dried formulations via spray-blending |
| HK1219059A1 (zh) * | 2013-03-15 | 2017-03-24 | 珍珠治疗公司 | 用於微粒晶体材料的状态调节的方法和系统 |
| US11554229B2 (en) | 2013-03-26 | 2023-01-17 | OptiNose Inc. | Nasal administration |
| WO2014165303A1 (en) | 2013-04-01 | 2014-10-09 | Pulmatrix, Inc. | Tiotropium dry powders |
| US9393202B2 (en) * | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| WO2014190204A1 (en) * | 2013-05-22 | 2014-11-27 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
| CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
| CN105636630B (zh) * | 2013-10-07 | 2020-05-19 | 梯瓦优质制药产品研发股份有限公司 | 干粉吸入器 |
| PL2897589T3 (pl) * | 2013-11-22 | 2018-06-29 | Teva Branded Pharmaceutical Products R & D, Inc. | Lek do inhalacji |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| GB201402556D0 (en) | 2014-02-13 | 2014-04-02 | Crystec Ltd | Improvements relating to inhalable particles |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| CN104188941B (zh) * | 2014-09-02 | 2016-11-16 | 重庆和平制药有限公司 | 一种制备盐酸克仑特罗吸入粉雾剂的方法 |
| KR20170057451A (ko) * | 2014-10-01 | 2017-05-24 | 에이엘에스 마운틴 엘엘씨 | 비이온성 계면 활성제와 함께 아스피린, 메트포르민 및 세로토닌을 포함하는 약학 조성물 |
| MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
| WO2016170518A1 (en) | 2015-04-24 | 2016-10-27 | Glenmark Specialty S.A. | Pharmaceutical compositions comprising arformoterol and glycopyrronium |
| WO2017108917A1 (en) | 2015-12-22 | 2017-06-29 | Astrazeneca Ab | Pharmaceutical compositions for use in the treatment of chronic obstructive pulmonary disease |
| WO2017157265A1 (zh) * | 2016-03-15 | 2017-09-21 | 广东东阳光药业有限公司 | 喷雾剂、喷雾装置以及喷雾组件 |
| WO2017201003A1 (en) * | 2016-05-17 | 2017-11-23 | Mayo Foundation For Medical Education And Research | Materials and methods for treating chronic cough |
| EP3478265B1 (en) | 2016-06-30 | 2025-01-01 | Philip Morris Products S.A. | Nicotine particles |
| US10888546B2 (en) * | 2016-09-19 | 2021-01-12 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| JP6906947B2 (ja) * | 2016-12-22 | 2021-07-21 | キヤノン株式会社 | 画像処理装置、撮像装置、画像処理方法およびコンピュータのプログラム |
| CN106943350A (zh) * | 2017-03-14 | 2017-07-14 | 上海现代药物制剂工程研究中心有限公司 | 含毒蕈碱受体拮抗剂和β2受体激动剂的气雾剂及制备方法 |
| CN107243080B (zh) * | 2017-06-21 | 2021-11-12 | 上海上药信谊药厂有限公司 | 一种吸入式气雾剂、其原料组合物及制备方法 |
| US11833292B2 (en) * | 2017-10-09 | 2023-12-05 | Pearl Therapeutics, Inc. | Drug delivery systems and related methods |
| JP7372727B2 (ja) | 2017-11-20 | 2023-11-01 | 三菱重工業株式会社 | 系統運用者側コンピュータ、発電事業者側コンピュータ、電力システム、制御方法及びプログラム |
| WO2020070620A2 (en) * | 2018-10-01 | 2020-04-09 | 3M Innovative Properties Company | Formulation and aerosol canisters, inhalers, and the like containing the formulation |
| US20210386665A1 (en) * | 2018-10-02 | 2021-12-16 | Meijo University Educational Foundation | Inhalation powder medicine, evaluation method thereof, and use thereof |
| CN109632555B (zh) * | 2018-12-28 | 2021-07-27 | 上海新黄河制药有限公司 | 一种富马酸福莫特罗无定型含量的动态蒸汽吸附分析方法 |
| WO2020229966A1 (en) * | 2019-05-10 | 2020-11-19 | Glenmark Pharmaceutical Limited | Stable aerosol composition for inhalation comprising glycopyrronium |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| WO2020263994A1 (en) * | 2019-06-27 | 2020-12-30 | Cai Gu Huang | Inhalable formulation of a solution containing formoterol fumarate and aclidinium bromide |
| CN112972384B (zh) * | 2019-12-02 | 2022-03-18 | 长风药业股份有限公司 | 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法 |
| WO2021165348A1 (en) * | 2020-02-20 | 2021-08-26 | Chiesi Farmaceutici S.P.A. | Pressurised metered dose inhalers comprising a buffered pharmaceutical formulation |
| EP3962455B1 (en) | 2020-05-18 | 2022-08-31 | Orexo AB | New pharmaceutical composition for drug delivery |
| US20220000767A1 (en) * | 2020-07-06 | 2022-01-06 | Sensory Cloud, Inc. | Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi |
| WO2022016068A1 (en) * | 2020-07-16 | 2022-01-20 | Tbd Pharma Llc | Dexamethasone solution for the treatment of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections |
| WO2022073009A1 (en) | 2020-09-29 | 2022-04-07 | iPharma Labs, Inc. | Liquid formulations of indacaterol |
| CN116710104A (zh) * | 2021-01-08 | 2023-09-05 | 江苏恒瑞医药股份有限公司 | 可通过定量吸入器递送的药物组合物 |
| JP2024049405A (ja) * | 2021-02-22 | 2024-04-10 | 興和株式会社 | 新規吸入剤 |
| ES2981514T3 (es) | 2021-07-09 | 2024-10-09 | Astrazeneca Pharmaceuticals Lp | Composiciones, métodos y sistemas para el suministro de fármacos en aerosol |
| WO2023094826A1 (en) | 2021-11-25 | 2023-06-01 | Orexo Ab | Pharmaceutical composition comprising adrenaline |
| GB202117016D0 (en) | 2021-11-25 | 2022-01-12 | Orexo Ab | New pharmaceutical device |
| WO2023119093A1 (en) | 2021-12-20 | 2023-06-29 | Astrazeneca Ab | Compositions, methods and systems for aerosol drug delivery |
| CN116785239A (zh) * | 2022-03-17 | 2023-09-22 | 上海惠永药物研究有限公司 | 喷雾冷冻干燥制备微球的方法 |
| JP2025518628A (ja) * | 2022-04-28 | 2025-06-18 | アストラゼネカ・アクチエボラーグ | 喘息の治療のための医薬組成物及び方法 |
| WO2024206662A1 (en) * | 2023-03-30 | 2024-10-03 | Aerorx Therapeutics Llc | Liquid formulations of indacaterol and glycopyrronium |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
| US20250268914A1 (en) * | 2024-02-26 | 2025-08-28 | Honeywell International Inc. | Fluticasone delivery compositions, devices and methods |
| CN118787617A (zh) * | 2024-09-14 | 2024-10-18 | 苏州易合医药有限公司 | 一种吸入粉剂及其制备方法 |
Family Cites Families (176)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2956062A (en) | 1959-02-26 | 1960-10-11 | Robins Co Inc A H | Esters of amino alcohols |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378109B (enExample) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US4187301A (en) | 1978-04-05 | 1980-02-05 | Syntex (U.S.A.) Inc. | 17 Beta-thiocarboxylic acid esters of 6 alpha, 6 beta-difluoro-3-oxoandrost-4-enes |
| CA1201114A (en) * | 1980-02-15 | 1986-02-25 | Gordon H. Phillipps | Androstane carbothioates |
| ATE8790T1 (de) * | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| ZW6584A1 (en) * | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| GB8432063D0 (en) | 1984-12-19 | 1985-01-30 | Riker Laboratories Inc | Physically modified steroids |
| US5707634A (en) | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
| GB8903593D0 (en) | 1989-02-16 | 1989-04-05 | Pafra Ltd | Storage of materials |
| EP0416950B1 (en) | 1989-09-08 | 1993-08-11 | Glaxo Group Limited | Medicaments |
| IL95590A (en) | 1989-09-08 | 1996-06-18 | Glaxo Group Ltd | Medicinal preparations containing Salmetrol and Pluticasone Propionate |
| DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| IE912999A1 (en) | 1990-09-07 | 1992-03-11 | Abbott Lab | Phenanthridine compounds |
| CA2091360C (en) | 1990-09-10 | 1997-04-08 | Pui-Ho Yuen | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| DE4108393A1 (de) | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
| US5635563A (en) | 1991-04-01 | 1997-06-03 | Tomoegawa Paper Co., Ltd. | Polyaniline derivatives and their production process |
| SE9302777D0 (sv) * | 1993-08-27 | 1993-08-27 | Astra Ab | Process for conditioning substances |
| AU659645B2 (en) | 1991-06-26 | 1995-05-25 | Inhale Therapeutic Systems | Storage of materials |
| SK282826B6 (sk) | 1991-12-18 | 2002-12-03 | Aktiebolaget Astra | Farmaceutická kompozícia na podávanie inhaláciou s obsahom formoterolu a budesonidu a jej použitie |
| US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
| US5849263A (en) | 1993-03-30 | 1998-12-15 | Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions containing alkylaryl polyether alcohol polymer |
| GB9313642D0 (en) * | 1993-07-01 | 1993-08-18 | Glaxo Group Ltd | Method and apparatus for the formation of particles |
| PT731688E (pt) | 1993-12-02 | 2003-07-31 | Abbott Lab | Formulacoes de farmacos em aerossol para utilizacao com propulsores sem cfc |
| SE9404080L (sv) | 1993-12-28 | 1995-06-29 | Ciba Geigy Ag | Förfarande för framställning av en optiskt ren enantiomer av formoterol |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| DE69502179D1 (de) | 1994-02-09 | 1998-05-28 | Kinerton Ltd | Verfahren zur trocknung eines materials aus einer lösung |
| GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
| DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| CN1088580C (zh) * | 1994-12-22 | 2002-08-07 | 阿斯特拉公司 | 气溶胶药物制剂 |
| US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
| GB9507768D0 (en) | 1995-04-13 | 1995-05-31 | Glaxo Group Ltd | Method of apparatus |
| KR19980703876A (ko) | 1995-04-14 | 1998-12-05 | 스티븐 엘. 허스트 | 분산성이 개선된 분말화된 약학적 조성물 |
| US6258341B1 (en) | 1995-04-14 | 2001-07-10 | Inhale Therapeutic Systems, Inc. | Stable glassy state powder formulations |
| US6309671B1 (en) | 1995-04-14 | 2001-10-30 | Inhale Therapeutic Systems | Stable glassy state powder formulations |
| US5833891A (en) * | 1996-10-09 | 1998-11-10 | The University Of Kansas | Methods for a particle precipitation and coating using near-critical and supercritical antisolvents |
| DE19614421C2 (de) | 1996-04-12 | 1999-12-16 | Biovision Gmbh | Verfahren zur Herstellung eines biodegradierbaren Knochenersatz- und Implantatwerkstoffes und biodegradierbarer Knochenersatz- und Implantatwerkstoff |
| GB9610821D0 (en) | 1996-05-23 | 1996-07-31 | Glaxo Wellcome Inc | Metering apparatus |
| US6054488A (en) | 1996-06-11 | 2000-04-25 | 3M Innovative Properties Company | Medicinal aerosol formulations of formoterol |
| GB9612297D0 (en) * | 1996-06-11 | 1996-08-14 | Minnesota Mining & Mfg | Medicinal aerosol formulations |
| US5886200A (en) * | 1996-07-01 | 1999-03-23 | Schering Corporation | Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones |
| US6068832A (en) | 1996-08-29 | 2000-05-30 | Schering Corporation | Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| US6040344A (en) | 1996-11-11 | 2000-03-21 | Sepracor Inc. | Formoterol process |
| DK0937041T3 (da) * | 1996-11-11 | 2003-08-11 | Christian R Noe | Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel |
| SE9700135D0 (sv) * | 1997-01-20 | 1997-01-20 | Astra Ab | New formulation |
| CZ295460B6 (cs) | 1997-03-20 | 2005-08-17 | Schering Corporation | Způsob výroby aglomerátů a jednotková dávka farmakologicky aktivní látky je obsahující |
| US6129905A (en) * | 1997-04-21 | 2000-10-10 | Aeropharm Technology, Inc. | Aerosol formulations containing a sugar as a dispersant |
| US6010935A (en) * | 1997-08-21 | 2000-01-04 | Micron Technology, Inc. | Self aligned contacts |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6433040B1 (en) * | 1997-09-29 | 2002-08-13 | Inhale Therapeutic Systems, Inc. | Stabilized bioactive preparations and methods of use |
| US20060165606A1 (en) * | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| US6946117B1 (en) * | 1997-09-29 | 2005-09-20 | Nektar Therapeutics | Stabilized preparations for use in nebulizers |
| ATE239447T1 (de) * | 1997-09-29 | 2003-05-15 | Inhale Therapeutic Syst | In verneblern verwendbare, stabilisierte zubereitungen |
| US6565885B1 (en) * | 1997-09-29 | 2003-05-20 | Inhale Therapeutic Systems, Inc. | Methods of spray drying pharmaceutical compositions |
| US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| BR9908566A (pt) | 1998-03-05 | 2000-11-21 | Senju Pharma Co | Composição farmacêutica para profilaxia e terapia de doenças associadas a citopatia do tecido do fundo ocular |
| SE9802073D0 (sv) | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| US6260549B1 (en) * | 1998-06-18 | 2001-07-17 | Clavius Devices, Inc. | Breath-activated metered-dose inhaler |
| US6451285B2 (en) | 1998-06-19 | 2002-09-17 | Baker Norton Pharmaceuticals, Inc. | Suspension aerosol formulations containing formoterol fumarate and a fluoroalkane propellant |
| US6585958B1 (en) | 1998-07-24 | 2003-07-01 | Jago Research Ag | Medicinal aerosol formulations |
| AU749697B2 (en) | 1998-08-04 | 2002-07-04 | Jagotec Ag | Medicinal aerosol formulations |
| CA2347856C (en) * | 1998-11-13 | 2009-02-17 | Jagotec Ag | Dry powder for inhalation |
| GB9912639D0 (en) | 1999-05-28 | 1999-07-28 | Britannia Pharmaceuticals Ltd | Improvements in and relating to treatment of respiratory conditions |
| GB9826284D0 (en) | 1998-12-01 | 1999-01-20 | Rhone Poulence Rorer Limited | Process |
| US6004537A (en) | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| EP2258183A1 (en) | 1998-12-22 | 2010-12-08 | The University of North Carolina at Chapel Hill | Compounds and uses for the treatment of airway diseases and for the delivery of airway drugs |
| GB9902689D0 (en) * | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
| GB9903759D0 (en) * | 1999-02-18 | 1999-04-14 | Novartis Ag | Organic compounds |
| GB9904919D0 (en) | 1999-03-03 | 1999-04-28 | Novartis Ag | Organic compounds |
| PL196951B1 (pl) | 1999-03-05 | 2008-02-29 | Chiesi Farma Spa | Proszek do stosowania w inhalatorze suchego proszku, cząsteczki nośnika i sposób wytwarzania nośnika |
| SE9900833D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| ES2193069T3 (es) | 1999-04-14 | 2003-11-01 | Glaxo Group Ltd | Formulacion farmaceutica en aerosol. |
| US20100197719A1 (en) | 1999-05-12 | 2010-08-05 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| HK1044130B (en) | 1999-06-30 | 2008-03-14 | Nektar Therapeutics | Spray drying process and system for preparing dry powders |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| PT102343B (pt) * | 1999-08-02 | 2003-11-28 | Hovione Farmaciencia Sa | Processo para a preparacao de furoato mometasona |
| US6586008B1 (en) * | 1999-08-25 | 2003-07-01 | Advanced Inhalation Research, Inc. | Use of simple amino acids to form porous particles during spray drying |
| CN1188111C (zh) | 1999-10-29 | 2005-02-09 | 耐科塔医药公司 | 分散性得到改进的干粉组合物 |
| DE19961300A1 (de) * | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| US6596261B1 (en) | 2000-01-25 | 2003-07-22 | Aeropharm Technology Incorporated | Method of administering a medicinal aerosol formulation |
| IT1317846B1 (it) * | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| GB0008660D0 (en) | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| AU2001252350A1 (en) | 2000-04-13 | 2001-10-30 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
| WO2001085136A2 (en) * | 2000-05-10 | 2001-11-15 | Alliance Pharmaceutical Corporation | Phospholipid-based powders for drug delivery |
| US20060257324A1 (en) | 2000-05-22 | 2006-11-16 | Chiesi Farmaceutici S.P.A. | Pharmaceutical solution formulations for pressurised metered dose inhalers |
| AU2000265583A1 (en) | 2000-08-15 | 2002-02-25 | Carsten Berg | Quaternary ammonium salts of 1,2-benzisothiazolin-3-one. preparation and use as biocides |
| FI20002215A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| US20040081627A1 (en) * | 2000-10-09 | 2004-04-29 | Jinks Phillip A | Medicinal aerosol formulations |
| US6908928B2 (en) | 2000-10-12 | 2005-06-21 | Bi Pharma Kg. | Crystalline tiotropium bromide monohydrate, processes for the preparation thereof, and pharmaceutical compositions |
| JP4380988B2 (ja) * | 2000-11-30 | 2009-12-09 | ヴェクトゥラ リミテッド | 医薬組成物に用いられる粒子の製造方法 |
| ES2587135T3 (es) | 2000-11-30 | 2016-10-20 | Vectura Limited | Procedimiento de fabricación de partículas para su uso en una composición farmacéutica |
| GB0029562D0 (en) | 2000-12-04 | 2001-01-17 | Novartis Ag | Organic compounds |
| AU2002230993B2 (en) | 2000-12-29 | 2006-02-02 | Alkermes, Inc. | Particles for inhalation having sustained release properties |
| US20020141946A1 (en) * | 2000-12-29 | 2002-10-03 | Advanced Inhalation Research, Inc. | Particles for inhalation having rapid release properties |
| ITMI20010428A1 (it) * | 2001-03-02 | 2002-09-02 | Chemo Breath S A | Composizioni ad uso inalatorio a base di formoterolo |
| IL157580A0 (en) * | 2001-03-20 | 2004-03-28 | Glaxo Group Ltd | Inhalation drug combination |
| US20050074742A1 (en) * | 2001-03-30 | 2005-04-07 | Alain Domard | Cartilaginous neo-tissue capable of being grafted |
| PT1372608E (pt) * | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US6848197B2 (en) | 2001-04-18 | 2005-02-01 | Advanced Inhalation Research, Inc. | Control of process humidity to produce large, porous particles |
| US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
| TWI324934B (en) * | 2001-08-28 | 2010-05-21 | Schering Corp | Pharmaceutical compositions for the treatment of asthma |
| DE10202940A1 (de) * | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| DE10214264A1 (de) * | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen eines Anhydrats |
| US7244415B2 (en) | 2002-03-28 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | HFA suspension formulations of an anhydrate |
| GB0207906D0 (en) | 2002-04-05 | 2002-05-15 | 3M Innovative Properties Co | Formoterol and mometasone aerosol formulations |
| DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
| AU2003276837B2 (en) * | 2002-06-12 | 2006-07-20 | Epigenesis Pharmaceuticals, Llc. | Combination of anti-muscarinic agents and non-glucocorticoid steroids |
| US7244742B2 (en) | 2002-08-17 | 2007-07-17 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Pharmaceutical compositions for inhalation containing an anticholinergic, corticosteroid and betamimetic |
| DE10237739A1 (de) | 2002-08-17 | 2004-02-26 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalative Arzneimittel enthaltend ein neues Anticholinergikum in Kombination mit Corticosteroiden und Betamimetika |
| CA2495689A1 (en) | 2002-08-23 | 2004-03-04 | Schering Corporation | Pharmaceutical compositions |
| CA2500065A1 (en) | 2002-09-30 | 2004-04-15 | Acusphere, Inc. | Sustained release porous microparticles for inhalation |
| ES2331793T3 (es) | 2002-10-15 | 2010-01-15 | Cryovac, Inc. | Procedimiento para estimular, almacenar y distribuir un captador de oxigeno, y un captador de oxigeno almacenado. |
| EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| DE10323966A1 (de) | 2003-05-27 | 2004-12-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen |
| CA2523475C (en) | 2003-05-28 | 2013-02-05 | Nektar Therapeutics | Pharmaceutical formulation comprising a water-insoluble active agent |
| WO2004110450A1 (en) * | 2003-06-16 | 2004-12-23 | Altana Pharma Ag | Composition comprising a pulmonary surfactant and a pde5 inhibitor for the treatment of lung diseases |
| SE527190C2 (sv) | 2003-06-19 | 2006-01-17 | Microdrug Ag | Inhalatoranordning samt kombinerade doser av en beta2-agonist, ett antikolinergiskt medel och ett antiinflammatorisk steroid |
| EP1651221B1 (en) | 2003-07-28 | 2009-01-14 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
| BRPI0413129A (pt) | 2003-07-29 | 2006-10-03 | Boehringer Ingelheim Int | medicamentos para inalação compreendendo betamiméticos e anticolinérgico |
| NZ545443A (en) | 2003-07-29 | 2010-04-30 | Boehringer Ingelheim Int | Combination of an aclidinium salt known as 3-(2-hydroxy-2,2-dithiophen-2-yl-acetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane and a steroid and its use to treat respiratory disorders by inhalation |
| ATE526967T1 (de) | 2003-07-31 | 2011-10-15 | Boehringer Ingelheim Int | Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum |
| EP1925293A3 (en) | 2003-10-20 | 2010-01-13 | Schering Corporation | Pharmaceutical aerosol compositions |
| US9308199B2 (en) * | 2004-04-29 | 2016-04-12 | Honeywell International Inc. | Medicament formulations |
| JP4851937B2 (ja) * | 2003-11-21 | 2012-01-11 | セラヴァンス， インコーポレーテッド | β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物 |
| SE0303270L (sv) * | 2003-12-03 | 2005-06-04 | Microdrug Ag | Metod för administration av tiotropium |
| CA2552641A1 (en) | 2003-12-31 | 2005-07-21 | Cydex, Inc. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| EP1718336B1 (en) | 2004-02-06 | 2008-06-25 | MEDA Pharma GmbH & Co. KG | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases |
| JP4819699B2 (ja) | 2004-02-06 | 2011-11-24 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 喘息及びｃｏｐｄの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤 |
| WO2005077339A1 (en) * | 2004-02-10 | 2005-08-25 | E.I. Dupont De Nemours And Company | Process for preparing stable sol of pharmaceutical ingredients and hydrofluorocarbon comprising milling the said sol, then transfert it into a canister |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| WO2006002178A1 (en) * | 2004-06-18 | 2006-01-05 | Novartis Vaccines And Diagnostics Inc. | Methods of treatment of endobronchial infections |
| GB0426301D0 (en) * | 2004-11-30 | 2004-12-29 | Vectura Ltd | Pharmaceutical formulations |
| US20060140873A1 (en) | 2004-12-27 | 2006-06-29 | Chang Heng W | Aerosol pharmaceutical compositions |
| EP1861361A1 (en) | 2005-03-24 | 2007-12-05 | Sosei R&D Ltd. | Glycopyrronium salts and their therapeutic use |
| MX2007012084A (es) | 2005-03-30 | 2007-11-21 | Schering Corp | Medicamentos y metodos que combinan un anticolinergico, un corticosteroide y un agonista beta de accion prolongada. |
| CA2607391A1 (en) | 2005-04-23 | 2006-11-02 | Boehringer Ingelheim International Gmbh | Combination of medicaments to be inhaled, containing a betamimetic agent and a steroid in addition to an anticholinergic agent |
| GB0523653D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| JP2008542332A (ja) | 2005-05-31 | 2008-11-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患治療用新規医薬組成物 |
| WO2006134022A1 (en) | 2005-06-17 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Mrp iv inhibitors for the treatment of respiratory diseases |
| AU2006272438B2 (en) | 2005-07-15 | 2011-08-04 | Map Pharmaceuticals, Inc. | Method of particle formation |
| US20100183725A1 (en) | 2005-07-15 | 2010-07-22 | Map Pharmaceuticals, Inc. | Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof |
| CN100560598C (zh) | 2005-07-26 | 2009-11-18 | 上海奥锐特国际贸易有限公司 | 氟替卡松丙酸酯的合成方法 |
| AT502396B1 (de) | 2005-09-01 | 2007-03-15 | Montanuniv Leoben | Verfahren zum abtrennen von verunreinigungen aus einsatzstoffen |
| GB0523656D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523655D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| GB0523654D0 (en) | 2005-11-21 | 2005-12-28 | Novartis Ag | Organic compounds |
| DE602006008665D1 (de) | 2005-12-21 | 2009-10-01 | Meda Pharma Gmbh & Co Kg | Kombination von r,r-glycopyrrolat, rolipram und budesonid zur behandlung von entzündungskrankheiten |
| US8263645B2 (en) * | 2006-02-03 | 2012-09-11 | Pari Pharma Gmbh | Disodium cromoglycate compositions and methods for administering same |
| AR059358A1 (es) * | 2006-02-09 | 2008-03-26 | Schering Corp | Formulaciones farmaceuticas |
| EP2029126A1 (en) | 2006-05-24 | 2009-03-04 | Boehringer Ingelheim International GmbH | Novel medicament combinations for the treatment of respiratory diseases |
| GB0613161D0 (en) * | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0614621D0 (en) | 2006-07-24 | 2006-08-30 | 3M Innovative Properties Co | Metered dose dispensers |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| EP2124915A2 (en) * | 2007-02-19 | 2009-12-02 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid |
| EP1964564A1 (en) * | 2007-04-19 | 2008-09-03 | LAB International SRL | Breakthrough Pain Management |
| EP2036572A1 (en) | 2007-09-04 | 2009-03-18 | Novo Nordisk A/S | Process for drying a protein, a protein particle and a pharmaceutical composition comprising the protein particle |
| CN101317821B (zh) * | 2007-11-15 | 2012-01-04 | 陈晓东 | 适用于肺部给药的超细干粉颗粒及其制备方法 |
| JP2011506399A (ja) * | 2007-12-13 | 2011-03-03 | ノバルティス アーゲー | 有機化合物 |
| GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
| FR2940162B1 (fr) | 2008-12-22 | 2011-02-25 | Boehm & Cie Ets | Outil de frappe multi-usages a mecanisme absorbant l'energie transmise au moyen de prehension |
| WO2010097188A1 (en) | 2009-02-25 | 2010-09-02 | Chiesi Farmaceutici S.P.A. | Inhalation particles comprising a salt of carmoterol and a corticosteroid |
| SI3106149T1 (sl) | 2009-05-29 | 2020-07-31 | Pearl Therapeutics, Inc. | Sestavki za pljučno dostavo muskarinskih antagonistov z dolgotrajnim delovanjem in agonistov beta-2 adrenergičnega receptorja z dolgotrajnim delovanjem in povezani postopki in sistemi |
| US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
| BR112012024059B1 (pt) | 2010-04-01 | 2021-06-01 | Chiesi Farmaceutici S.P.A. | Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco |
| EP2627317A4 (en) | 2010-10-15 | 2014-08-20 | Glaxo Group Ltd | MEDICINAL FORMULATIONS FROM AGGREGATED NANOPARTICLES AND THEIR PREPARATION AND USE |
| RU2013142268A (ru) | 2011-02-17 | 2015-03-27 | Сипла Лимитед | Фармацевтическая композиция |
| JO3510B1 (ar) | 2011-03-04 | 2020-07-05 | Heptares Therapeutics Ltd | استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب |
| MX2013013440A (es) | 2011-05-17 | 2014-06-05 | Pearl Therapeutics Inc | Composiciones, metodos y sistemas para suministro respiratorio de dos o mas agentes activos. |
| WO2014190204A1 (en) | 2013-05-22 | 2014-11-27 | Pearl Therapeutics, Inc. | Compositions, methods & systems for respiratory delivery of three or more active agents |
-
2010
- 2010-05-28 SI SI201031975T patent/SI3106149T1/sl unknown
- 2010-05-28 TW TW107126090A patent/TWI695723B/zh active
- 2010-05-28 HU HUE16164845A patent/HUE047834T2/hu unknown
- 2010-05-28 WO PCT/US2010/036650 patent/WO2010138862A2/en not_active Ceased
- 2010-05-28 ES ES10727553.9T patent/ES2593429T3/es active Active
- 2010-05-28 PT PT107275513T patent/PT2435024T/pt unknown
- 2010-05-28 CA CA2763939A patent/CA2763939A1/en not_active Abandoned
- 2010-05-28 PL PL16164849T patent/PL3111927T3/pl unknown
- 2010-05-28 HU HUE10727551A patent/HUE031229T2/en unknown
- 2010-05-28 BR BRPI1011220-0A patent/BRPI1011220B1/pt active IP Right Grant
- 2010-05-28 PL PL16164844T patent/PL3111926T3/pl unknown
- 2010-05-28 ME MEP-2020-37A patent/ME03631B/me unknown
- 2010-05-28 CN CN201610862606.5A patent/CN107412212B/zh active Active
- 2010-05-28 SM SM20200108T patent/SMT202000108T1/it unknown
- 2010-05-28 CN CN201080033312.2A patent/CN102753152B/zh active Active
- 2010-05-28 DK DK10721258.1T patent/DK2435023T3/en active
- 2010-05-28 PT PT161648498T patent/PT3111927T/pt unknown
- 2010-05-28 BR BRPI1011229A patent/BRPI1011229B8/pt active IP Right Grant
- 2010-05-28 US US12/790,605 patent/US8808713B2/en active Active
- 2010-05-28 SI SI201031262A patent/SI2435025T1/sl unknown
- 2010-05-28 TW TW105111487A patent/TWI646980B/zh active
- 2010-05-28 SM SM20200077T patent/SMT202000077T1/it unknown
- 2010-05-28 CN CN201710722981.4A patent/CN107669664B/zh active Active
- 2010-05-28 CN CN201080033311.8A patent/CN102458364B/zh active Active
- 2010-05-28 EP EP10727551.3A patent/EP2435024B1/en active Active
- 2010-05-28 DK DK16164845.6T patent/DK3106149T3/da active
- 2010-05-28 LT LTEP16164845.6T patent/LT3106149T/lt unknown
- 2010-05-28 TW TW107143778A patent/TWI707700B/zh active
- 2010-05-28 PL PL10727553T patent/PL2435025T3/pl unknown
- 2010-05-28 KR KR1020197012625A patent/KR20190049943A/ko not_active Ceased
- 2010-05-28 AU AU2010253770A patent/AU2010253770B9/en active Active
- 2010-05-28 KR KR1020117028582A patent/KR20120015334A/ko not_active Ceased
- 2010-05-28 LT LTEP16164844.9T patent/LT3111926T/lt unknown
- 2010-05-28 SI SI201031985T patent/SI3111926T1/sl unknown
- 2010-05-28 SI SI201031263A patent/SI2435023T1/sl unknown
- 2010-05-28 KR KR1020177024590A patent/KR101926060B1/ko active Active
- 2010-05-28 TW TW110100317A patent/TWI792140B/zh active
- 2010-05-28 US US12/790,448 patent/US9463161B2/en active Active
- 2010-05-28 LT LTEP16164849.8T patent/LT3111927T/lt unknown
- 2010-05-28 TW TW099117221A patent/TWI632926B/zh active
- 2010-05-28 AR ARP100101885A patent/AR076621A1/es not_active Application Discontinuation
- 2010-05-28 DK DK16164844.9T patent/DK3111926T3/da active
- 2010-05-28 AR ARP100101884A patent/AR076807A1/es not_active Application Discontinuation
- 2010-05-28 LT LTEP10721258.1T patent/LT2435023T/lt unknown
- 2010-05-28 MX MX2020004077A patent/MX393243B/es unknown
- 2010-05-28 PT PT161648456T patent/PT3106149T/pt unknown
- 2010-05-28 PT PT107212581T patent/PT2435023T/pt unknown
- 2010-05-28 MX MX2011012684A patent/MX350163B/es active IP Right Grant
- 2010-05-28 HU HUE16164844A patent/HUE047803T2/hu unknown
- 2010-05-28 SI SI201031260A patent/SI2435024T1/sl unknown
- 2010-05-28 MX MX2011012783A patent/MX337126B/es active IP Right Grant
- 2010-05-28 KR KR1020177016074A patent/KR20170070274A/ko not_active Ceased
- 2010-05-28 US US12/790,710 patent/US20110132357A1/en not_active Abandoned
- 2010-05-28 PL PL16164845T patent/PL3106149T3/pl unknown
- 2010-05-28 SM SM20200109T patent/SMT202000109T1/it unknown
- 2010-05-28 WO PCT/US2010/036659 patent/WO2010138868A2/en not_active Ceased
- 2010-05-28 HR HRP20161098TT patent/HRP20161098T1/hr unknown
- 2010-05-28 HU HUE10727553A patent/HUE029532T2/en unknown
- 2010-05-28 ES ES10721258.1T patent/ES2592536T3/es active Active
- 2010-05-28 CN CN201080033310.3A patent/CN102596176B/zh active Active
- 2010-05-28 JP JP2012513314A patent/JP5823383B2/ja active Active
- 2010-05-28 ES ES16164844T patent/ES2774391T3/es active Active
- 2010-05-28 PT PT107275539T patent/PT2435025T/pt unknown
- 2010-05-28 RU RU2016107464A patent/RU2751771C2/ru active
- 2010-05-28 TW TW099117220A patent/TWI539979B/zh active
- 2010-05-28 TW TW105116641A patent/TWI633898B/zh active
- 2010-05-28 PL PL10727551T patent/PL2435024T3/pl unknown
- 2010-05-28 KR KR1020117028551A patent/KR101748892B1/ko active Active
- 2010-05-28 AR ARP100101882A patent/AR076806A1/es not_active Application Discontinuation
- 2010-05-28 DK DK16164849.8T patent/DK3111927T3/da active
- 2010-05-28 US US12/790,671 patent/US20110135737A1/en not_active Abandoned
- 2010-05-28 JP JP2012513319A patent/JP5873013B2/ja active Active
- 2010-05-28 LT LTEP10727551.3T patent/LT2435024T/lt unknown
- 2010-05-28 PL PL10721258T patent/PL2435023T3/pl unknown
- 2010-05-28 EP EP16164844.9A patent/EP3111926B1/en active Active
- 2010-05-28 JP JP2012513311A patent/JP5873012B2/ja active Active
- 2010-05-28 HR HRP20161101TT patent/HRP20161101T1/hr unknown
- 2010-05-28 AU AU2010253950A patent/AU2010253950C1/en active Active
- 2010-05-28 LT LTEP10727553.9T patent/LT2435025T/lt unknown
- 2010-05-28 EP EP10727553.9A patent/EP2435025B1/en active Active
- 2010-05-28 CA CA2763936A patent/CA2763936C/en active Active
- 2010-05-28 HU HUE10721258A patent/HUE031283T2/hu unknown
- 2010-05-28 PT PT161648449T patent/PT3111926T/pt unknown
- 2010-05-28 EP EP16164845.6A patent/EP3106149B1/en active Active
- 2010-05-28 ES ES16164849T patent/ES2774367T3/es active Active
- 2010-05-28 ES ES10727551.3T patent/ES2589135T3/es active Active
- 2010-05-28 WO PCT/US2010/036676 patent/WO2010138884A2/en not_active Ceased
- 2010-05-28 ES ES16164845T patent/ES2772253T3/es active Active
- 2010-05-28 KR KR1020187034755A patent/KR20180130602A/ko not_active Abandoned
- 2010-05-28 MX MX2011012685A patent/MX350164B/es active IP Right Grant
- 2010-05-28 EP EP10721258.1A patent/EP2435023B1/en active Active
- 2010-05-28 EP EP16164849.8A patent/EP3111927B1/en active Active
- 2010-05-28 DK DK10727553.9T patent/DK2435025T3/en active
- 2010-05-28 CN CN201510450391.1A patent/CN105193773B/zh active Active
- 2010-05-28 RU RU2016117972A patent/RU2016117972A/ru not_active Application Discontinuation
- 2010-05-28 SI SI201031984T patent/SI3111927T1/sl unknown
- 2010-05-28 HU HUE16164849A patent/HUE047823T2/hu unknown
- 2010-05-28 KR KR1020117028583A patent/KR101976107B1/ko active Active
- 2010-05-28 RU RU2011154083A patent/RU2580315C3/ru active Protection Beyond IP Right Term
- 2010-05-28 HR HRP20161102TT patent/HRP20161102T1/hr unknown
- 2010-05-28 DK DK10727551.3T patent/DK2435024T3/en active
- 2010-05-28 MX MX2017011058A patent/MX377778B/es unknown
- 2010-05-28 AU AU2010253776A patent/AU2010253776B2/en active Active
- 2010-05-28 BR BRPI1011508A patent/BRPI1011508A2/pt not_active Application Discontinuation
- 2010-05-28 TW TW099117219A patent/TWI546094B/zh active
- 2010-05-28 CA CA2763941A patent/CA2763941A1/en not_active Abandoned
- 2010-05-28 TW TW106115156A patent/TWI717511B/zh active
- 2010-05-28 RU RU2015151358A patent/RU2713404C2/ru active
-
2011
- 2011-11-10 ZA ZA2011/08275A patent/ZA201108275B/en unknown
- 2011-11-20 IL IL216466A patent/IL216466B/en active IP Right Grant
- 2011-11-20 IL IL216468A patent/IL216468B/en active IP Right Grant
- 2011-11-20 IL IL216467A patent/IL216467B/en active IP Right Grant
-
2012
- 2012-10-26 ZA ZA2012/08101A patent/ZA201208101B/en unknown
- 2012-10-26 ZA ZA2012/08100A patent/ZA201208100B/en unknown
- 2012-10-26 ZA ZA2012/08102A patent/ZA201208102B/en unknown
-
2014
- 2014-07-09 US US14/327,425 patent/US20150017247A1/en not_active Abandoned
-
2015
- 2015-04-16 JP JP2015084226A patent/JP6169639B2/ja active Active
- 2015-04-16 JP JP2015084240A patent/JP6189356B2/ja active Active
- 2015-10-07 JP JP2015199079A patent/JP2016041713A/ja not_active Withdrawn
-
2016
- 2016-04-21 US US15/135,389 patent/US20170071850A1/en not_active Abandoned
- 2016-08-30 US US15/252,001 patent/US20170112759A1/en not_active Abandoned
- 2016-09-20 SM SM201600327T patent/SMT201600327B/it unknown
- 2016-09-20 SM SM201600326T patent/SMT201600326B/it unknown
- 2016-09-21 CY CY20161100939T patent/CY1118040T1/el unknown
- 2016-09-21 SM SM201600329T patent/SMT201600329B/it unknown
- 2016-09-21 CY CY20161100941T patent/CY1118030T1/el unknown
- 2016-09-21 CY CY20161100940T patent/CY1118034T1/el unknown
-
2017
- 2017-04-26 PH PH12017500778A patent/PH12017500778A1/en unknown
- 2017-06-15 US US15/624,597 patent/US20180125776A1/en not_active Abandoned
- 2017-06-28 JP JP2017125969A patent/JP6492124B2/ja active Active
- 2017-08-02 JP JP2017149555A patent/JP6348645B2/ja active Active
- 2017-09-28 JP JP2017188628A patent/JP2018048150A/ja active Pending
-
2018
- 2018-02-16 US US15/932,249 patent/US20190038548A1/en not_active Abandoned
- 2018-11-02 US US16/179,712 patent/US10716753B2/en active Active
-
2019
- 2019-03-04 JP JP2019038501A patent/JP6876734B2/ja active Active
- 2019-06-06 CY CY2019031C patent/CY2019031I2/el unknown
- 2019-06-12 LU LU00124C patent/LUC00124I2/fr unknown
- 2019-06-12 HU HUS1900031C patent/HUS1900031I1/hu unknown
- 2019-06-12 FR FR19C1040C patent/FR19C1040I2/fr active Active
- 2019-06-13 NO NO2019026C patent/NO2019026I1/no unknown
- 2019-06-14 NL NL300995C patent/NL300995I2/nl unknown
- 2019-06-17 LT LTPA2019014C patent/LTC2435025I2/lt unknown
-
2020
- 2020-01-24 RU RU2020102859A patent/RU2020102859A/ru unknown
- 2020-01-31 HR HRP20200166TT patent/HRP20200166T1/hr unknown
- 2020-02-14 CY CY20201100136T patent/CY1122749T1/el unknown
- 2020-02-17 HR HRP20200260TT patent/HRP20200260T1/hr unknown
- 2020-02-21 HR HRP20200298TT patent/HRP20200298T1/hr unknown
- 2020-02-25 CY CY20201100173T patent/CY1122732T1/el unknown
- 2020-02-28 CY CY20201100185T patent/CY1122807T1/el unknown
- 2020-08-03 US US16/983,543 patent/US20210186861A1/en not_active Abandoned
-
2021
- 2021-05-10 CY CY2021012C patent/CY2021012I1/el unknown
- 2021-05-12 NO NO2021019C patent/NO2021019I1/no unknown
- 2021-05-12 HU HUS2100018C patent/HUS2100018I1/hu unknown
- 2021-05-19 LU LU00208C patent/LUC00208I2/fr unknown
- 2021-06-04 LT LTPA2021511C patent/LTC2435024I2/lt unknown
-
2024
- 2024-02-20 US US18/582,344 patent/US20250009652A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012528792A5 (enExample) | ||
| JP2012528199A5 (enExample) | ||
| JP2012528200A5 (enExample) | ||
| RU2011154083A (ru) | Композиции для респираторной доставки активных веществ и связанные с ними способы и системы | |
| ES2981514T3 (es) | Composiciones, métodos y sistemas para el suministro de fármacos en aerosol | |
| JP2016041713A5 (enExample) | ||
| US20150150787A1 (en) | Compositions, methods & systems for respiratory delivery of three or more active agents | |
| JP2017515835A (ja) | Ｃｏｐｄの治療のためのチオトロピウムブロミド、フォルモテロール及びブデソニドの組み合わせ | |
| JP5938476B2 (ja) | 呼吸器疾患を治療するための定量噴霧式吸入剤を調製する方法 | |
| CN117915893A (zh) | 用于气溶胶药物递送的组合物、方法和系统 | |
| US20250057764A1 (en) | Compositions, methods and systems for aerosol drug delivery | |
| TW202525298A (zh) | 一種吸入性醫藥製劑、裝置及其用途 | |
| HK1176550A (en) | The preparation for formulation composition and manufacturing processes of metered does inhalers treated respiratory diseases |